⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNDX News
Syndax Pharmaceuticals, Inc.
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
globenewswire.com
SNDX
Ligand Reports First Quarter 2026 Financial Results
globenewswire.com
LGND
XOMA
MRK
SNDX
AGEN
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX
Form 8-K
sec.gov
SNDX
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
SNDX
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
globenewswire.com
SNDX
Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight
globenewswire.com
EDSA
VERU
PLTR
HLIO
DRCT
BHVN
CART
AMGN
AROW
AZN
GSK
NVS
SNDX
SNY
UNH
VRTX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX
サムスンバイオエピス、サンドと次世代バイオシミラー候補最大 5 品目に関するパートナーシップ契約を締結
businesswire.com
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX